BrightHeart Unveils Innovative AI Research in Maternal Care

BrightHeart to Present Groundbreaking AI Research at SMFM

BrightHeart, an innovative leader in AI technology for obstetric and pediatric cardiology, is thrilled to announce the presentation of its two pioneering studies at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting scheduled from January 27th to February 1st in Aurora, Colorado. These studies reveal powerful advancements in the use of AI for identifying serious congenital heart defects during routine fetal anatomy scans conducted in the second trimester.

Congenital heart defects (CHDs) are recognized as the most prevalent birth defects, impacting about 1% of newborns. Alarmingly, detection rates during prenatal examinations remain inadequate, with approximately 70% of cases remaining undiagnosed until after birth. This missed opportunity can lead to delays in necessary medical care, resulting in poorer health outcomes for both mother and child. BrightHeart is committed to addressing this diagnostic shortfall by equipping healthcare providers with state-of-the-art AI tools aimed at enhancing the precision and timing of CHD detection.

The studies, conducted in collaboration with esteemed academic institutions and medical practitioners, have been selected for presentation in two prominent sessions at the conference, out of more than 2,000 submissions.

Session 1: Oral Plenary Session I

Title: “AI Significantly Improves Detection of Prenatal Ultrasounds Suspicious for Major Congenital Heart Defects by OBGYN/MFMs”
Date: Thursday, January 30, 2025
Time: 8:45 AM – 9:00 AM MST
Presenter: Dr. Jennifer Lam-Rachlin, MD, an Assistant Professor in Maternal-Fetal Medicine at a prestigious medical school, and Director of Fetal Echocardiography.

Session 2: Oral Concurrent Session 3 – Ultrasound and Genetics

Title: “Artificial Intelligence System Accurately Detects Fetal Ultrasound Findings Suspicious for Major Congenital Heart Defects”
Date: Thursday, January 30, 2025
Time: 1:45 PM – 2:00 PM MST
Presenter: Dr. Carolyn M. Zelop, MD, Clinical Professor of OB/GYN.

Cécile Dupont, CEO of BrightHeart, expressed excitement about the upcoming presentation, stating, "We are proud to share our groundbreaking clinical results at the SMFM 2025 Pregnancy Meeting. Our findings illustrate how BrightHeart’s AI can redefine prenatal detection of congenital heart defects. Being chosen for the plenary session reflects the significant impact of our research and the strength of our clinical partnerships."

Dr. Jennifer Lam-Rachlin emphasized the transformative potential of innovative technology in prenatal care, saying, "AI-driven solutions like BrightHeart’s can alter the clinical landscape for diagnosing congenital heart defects, providing clinicians essential tools to better patient outcomes." Furthermore, Dr. Carolyn M. Zelop remarked on the technology's empowering nature, suggesting it allows for timely diagnosis and improved care decisions that ultimately benefit families.

These presentations follow BrightHeart’s recent milestone of obtaining FDA 510(k) clearance for its AI software designed for fetal heart ultrasound evaluations. Highlighting the outcomes at the SMFM 2025 Pregnancy Meeting positions BrightHeart to revolutionize clinical workflows, facilitate earlier diagnoses, and enhance comprehensive care planning.

About BrightHeart
BrightHeart SAS is a Paris-based, privately held medical device company, part of Sofinnova MD Start, which acts as a medical device incubator under Sofinnova Partners. The software developed by BrightHeart leverages cutting-edge AI technology to analyze fetal heart ultrasound examinations. It supports medical professionals in the prenatal identification of congenital heart defects, ultimately striving to enhance pregnancy outcomes through proactive care and early intervention.

With a foundation of over a decade's worth of innovation and excellence in fetal cardiology training, co-founders Dr. Marilyne Levy and Dr. Bertrand Stos are recognized as leading specializations in fetal cardiology, based in Paris, France.

Frequently Asked Questions

What is BrightHeart's main focus with its AI technology?

BrightHeart focuses on using AI to enhance the detection of congenital heart defects during prenatal care, thereby improving outcomes for mothers and babies.

Why is early detection of congenital heart defects important?

Early detection is crucial to ensure timely medical intervention, reducing risks and enhancing health outcomes for both the mother and the baby.

What prestigious event will BrightHeart present its research?

BrightHeart's groundbreaking research will be presented at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting.

Who are the presenters of the studies?

The studies will be presented by Dr. Jennifer Lam-Rachlin and Dr. Carolyn M. Zelop, both esteemed professionals in their field.

What recent achievement did BrightHeart accomplish?

BrightHeart recently received FDA 510(k) clearance for its first AI software designed for fetal heart ultrasound evaluations.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.